113 related articles for article (PubMed ID: 15459004)
1. Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin.
Albert MH; Yu XZ; Martin PJ; Anasetti C
Blood; 2005 Feb; 105(3):1355-61. PubMed ID: 15459004
[TBL] [Abstract][Full Text] [Related]
2. CD28-specific antibody prevents graft-versus-host disease in mice.
Yu XZ; Bidwell SJ; Martin PJ; Anasetti C
J Immunol; 2000 May; 164(9):4564-8. PubMed ID: 10779758
[TBL] [Abstract][Full Text] [Related]
3. Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation.
Dengler TJ; Szabo G; Sido B; Nottmeyer W; Zimmerman R; Vahl CF; Hünig T; Meuer SC
Transplantation; 1999 Feb; 67(3):392-8. PubMed ID: 10030284
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
5. CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens.
Yu XZ; Albert MH; Martin PJ; Anasetti C
J Clin Invest; 2004 Jun; 113(11):1624-30. PubMed ID: 15173889
[TBL] [Abstract][Full Text] [Related]
6. GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression.
Miller WP; Srinivasan S; Panoskaltsis-Mortari A; Singh K; Sen S; Hamby K; Deane T; Stempora L; Beus J; Turner A; Wheeler C; Anderson DC; Sharma P; Garcia A; Strobert E; Elder E; Crocker I; Crenshaw T; Penedo MC; Ward T; Song M; Horan J; Larsen CP; Blazar BR; Kean LS
Blood; 2010 Dec; 116(24):5403-18. PubMed ID: 20833977
[TBL] [Abstract][Full Text] [Related]
7. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
8. Acute graft-versus-host disease without costimulation via CD28.
Speiser DE; Bachmann MF; Shahinian A; Mak TW; Ohashi PS
Transplantation; 1997 Apr; 63(7):1042-4. PubMed ID: 9112366
[TBL] [Abstract][Full Text] [Related]
9. CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates.
Watkins BK; Tkachev V; Furlan SN; Hunt DJ; Betz K; Yu A; Brown M; Poirier N; Zheng HB; Taraseviciute A; Colonna L; Mary C; Blancho G; Soulillou JP; Panoskaltsis-Mortari A; Sharma P; Garcia A; Strobert E; Hamby K; Garrett A; Deane T; Blazar BR; Vanhove B; Kean LS
J Clin Invest; 2018 Aug; 128(9):3991-4007. PubMed ID: 30102255
[TBL] [Abstract][Full Text] [Related]
10. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF
Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571
[TBL] [Abstract][Full Text] [Related]
11. Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease.
Beyersdorf N; Ding X; Hünig T; Kerkau T
Blood; 2009 Nov; 114(20):4575-82. PubMed ID: 19721011
[TBL] [Abstract][Full Text] [Related]
12. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease.
Hippen KL; Watkins B; Tkachev V; Lemire AM; Lehnen C; Riddle MJ; Singh K; Panoskaltsis-Mortari A; Vanhove B; Tolar J; Kean LS; Blazar BR
Transplantation; 2016 Dec; 100(12):2630-2639. PubMed ID: 27861291
[TBL] [Abstract][Full Text] [Related]
14. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
17. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
Blazar BR; Taylor PA; Vallera DA
J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
[TBL] [Abstract][Full Text] [Related]
18. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD.
Jacobsohn DA; Vogelsang GB
Drugs; 2002; 62(6):879-89. PubMed ID: 11929336
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
Nunes NS; Kanakry CG
Front Immunol; 2019; 10():2668. PubMed ID: 31849930
[TBL] [Abstract][Full Text] [Related]
20. Induction of immunologic tolerance for allogeneic hematopoietic cell transplantation.
Appleman LJ; Tzachanis D; Grader-Beck T; Van Puijenbroek AA; Boussiotis VA
Leuk Lymphoma; 2002 Jun; 43(6):1159-67. PubMed ID: 12152983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
